Article · 22 Aug 2025
Conference abstractPublished 31 Jan 2020
Five day Accelerated Partial Breast Irradiation (APBI) using Stereotactic Body Irradiation Therapy (SBRT) in stage 0-II breast cancer: A preliminary report of 69 cases
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Randomized trials in Stage 0-II breast cancer with 10 year follow-up have proven that Accelerated Partial Breast Irradiation (APBI) given via radiation implant in 5 days is equivalent to Whole Breast Radiation Therapy (WBRT) in 6 weeks in regard to tumor local recurrence (LR). However, implants are invasive and complications, including infection and soft tissue necrosis requiring possible mastectomy have been significant. Recently APBI using non-invasive Intensity Modulated Radiation Therapy (IMRT) in 5 days was shown to be equivalent to WBRT in 6 weeks with 5 year follow-up, with respect to LR. APBI IMRT was superior in regard to side effects, and cosmesis. Objectives: In the randomized clinical trial of APBI IMRT, the Clinical Target Volume (CTV) was defined by the injection of individual fiducial markers bordering the surgical cavity. We have used the simpler less labor intensive Biozorb fiducial system to localize the CTV for SBRT. Materials and Methods: Between 2017 and 2019, 69 patients underwent SBRT targeted to Biozorb defined CTV. Eligible patients were older than age 40, had tumor sizes < 3 cm, negative surgical margins, and negative node dissections. SBRT dose was 30 Gy given in 5 fractions. The Planning Target Volume (PTV) ranged from 27 to 355 cc with a median of 80 cc. PTV = CTV + 1-2 cm. Results: Follow-up ranged from 1-18 months with a median of 9 months. LR has been 0% (0/69). There were no skin reactions. Cosmetic results were rated excellent in 100% (69/69) of cases. Conclusions: Non-invasive APBI with SBRT given over 5 days targeted to Biozorb has resulted in LR, complications, and cosmetic results which compare favorably to invasive APBI given via implant. At last follow-up, there have been no LR, skin reactions, or complications. Cosmesis has been excellent in 100% of patients.
Keywords
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Cancer & Metastasis Research.
Article · 21 Jan 2025
Advances in metastasis research and implications for cancer therapy
Case report · 4 Aug 2023
A extremely unusual testicular tumour case report
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Cancer & Metastasis Research
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Rufus Mark”
